Pfizer Announces New Study and 1 Stock Riding 52-Week Highs

Northrop Grumman Corp. (NYSE:NOC): Northrop Grumman Corp. has been awarded a $50.6 million contract to supply the Machinery Control System, or MCS, for the U.S. Navy’s LHA-7 amphibious assault ship by prime contractor Huntington Ingalls Industries (HII). The MCS controls the major shipboard systems including the highly automated propulsion, electric plant and fuel fill systems. The equipment being supplied includes 56 data acquisition units, 27 workstations and 1,125 fire sensors located throughout the vessel. The work will be performed chiefly in Charlottesville and the MCS will be installed on the LHA-7 at HII’s shipyard in Pascagoula, Mississippi before delivery to the Navy. Equipment deliveries are expected to begin in 2014 and continue into 2016, with installations to follow. Their shares closed at $70.60, up $0.24 or 0.34% on the day. They have traded in a 52-week range of $52.69 to $70.58.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

Pfizer (NYSE:PFE): Pfizer announced that a Phase 3 study of Inlyta did not meet its primary endpoint of demonstrating a statistically significant, longer progression-free survival as opposed to Sorafenib, in treatment-naive patients with advanced Renal Cell Carcinoma. A preliminary review of the data showed that overall, the median PFS for Inlyta exceeded the median PFS for Sorafenib, but did not meet statistical significance. In a pre-specified subgroup of patients classified as good Performance Status, the median PFS for Inlyta exceeded the median PFS for Sorafenib. In another pre-specified subgroup of patients classified as intermediate Performance Status, there was no difference between Inlyta and Sorafenib. Their shares closed at $25.84, up $0.04 or 0.16% on the day. They have traded in a 52-week range of $18.15 to $25.93.

Don’t Miss: Here’s How Arena Put Analysts On The Edge of Their Seats.